Literature DB >> 19381722

Toll-like receptor 2 gene polymorphisms Arg677Trp and Arg753Gln in chronic obstructive pulmonary disease.

Stefan Pabst1, Vildan Yenice, Martina Lennarz, Izabela Tuleta, Georg Nickenig, Adrian Gillissen, Christian Grohé.   

Abstract

Chronic obstructive pulmonary disease (COPD) is a leading cause of death worldwide, with a continually rising mortality rate. As COPD is driven by abnormal pulmonary and systemic inflammation, Toll-like receptors (TLRs) seem to be important. TLRs play a key role in innate response, and in particular TLR2 gene polymorphisms Arg677Trp and Arg753Gln have been linked to an increased risk of infection. The purpose of this study was to investigate whether there is a link between polymorphisms in TLR2 and the onset or course of COPD. We analyzed 149 Caucasian COPD patients and 150 healthy individuals by using polymerase chain reaction (PCR) followed by restriction fragment length polymorphism (RFLP) analysis. To further characterize the disease, patients were classified according to GOLD and divided into two subgroups comprising a stable (60/149) course and an unstable (89/149) course. The TLR2 Arg677Trp mutant allele was not found in any of the subjects. With a prevalence of 8.72% (13/149) for TLR2 Arg753Gln, the patients did not differ from the controls, with a prevalence of 10.67% (16/150). No significant difference was apparent (P = 0.571). None of the individuals showed homozygosity for TLR2 Arg753Gln. With regard to the course of COPD, the prevalence of TLR2 Arg753Gln in the control group did not differ significantly either from the stable subgroup (P = 0.196) or from the unstable subgroup (P = 0.891). Our results suggest that there is no association of the TLR2 polymorphisms Arg677Trp and Arg753Gln with either the onset or the course of COPD.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19381722     DOI: 10.1007/s00408-009-9144-8

Source DB:  PubMed          Journal:  Lung        ISSN: 0341-2040            Impact factor:   2.584


  33 in total

1.  Risk factors for lower airway bacterial colonization in chronic bronchitis.

Authors:  E Monsó; A Rosell; G Bonet; J Manterola; P J Cardona; J Ruiz; J Morera
Journal:  Eur Respir J       Date:  1999-02       Impact factor: 16.671

2.  Toll-like receptor (TLR) 2 and 4 mutations in periodontal disease.

Authors:  M Folwaczny; J Glas; H-P Török; O Limbersky; C Folwaczny
Journal:  Clin Exp Immunol       Date:  2004-02       Impact factor: 4.330

Review 3.  Genetic polymorphisms in chronic obstructive pulmonary disease.

Authors:  Rasa Ugenskiene; Marek Sanak; Raimundas Sakalauskas; Andrew Szczeklik
Journal:  Medicina (Kaunas)       Date:  2005       Impact factor: 2.430

4.  Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial.

Authors:  P S Burge; P M Calverley; P W Jones; S Spencer; J A Anderson; T K Maslen
Journal:  BMJ       Date:  2000-05-13

5.  Chronic obstructive pulmonary disease is associated with the -1055 IL-13 promoter polymorphism.

Authors:  T C T M van der Pouw Kraan; M Küçükaycan; A M Bakker; J M C Baggen; J S van der Zee; M A Dentener; E F M Wouters; C L Verweij
Journal:  Genes Immun       Date:  2002-11       Impact factor: 2.676

Review 6.  The importance of Toll-like receptor 2 polymorphisms in severe infections.

Authors:  Joelle Texereau; Jean-Daniel Chiche; William Taylor; Gerald Choukroun; Beatrice Comba; Jean-Paul Mira
Journal:  Clin Infect Dis       Date:  2005-11-15       Impact factor: 9.079

7.  Cutting edge: a Toll-like receptor 2 polymorphism that is associated with lepromatous leprosy is unable to mediate mycobacterial signaling.

Authors:  Pierre-Yves Bochud; Thomas R Hawn; Alan Aderem
Journal:  J Immunol       Date:  2003-04-01       Impact factor: 5.422

8.  Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease.

Authors:  G C Donaldson; T A R Seemungal; A Bhowmik; J A Wedzicha
Journal:  Thorax       Date:  2002-10       Impact factor: 9.139

9.  High frequency of polymorphism Arg753Gln of the Toll-like receptor-2 gene detected by a novel allele-specific PCR.

Authors:  Nicolas W J Schröder; Corinna Hermann; Lutz Hamann; Ulf B Göbel; Thomas Hartung; Ralf R Schumann
Journal:  J Mol Med (Berl)       Date:  2003-05-13       Impact factor: 4.599

Review 10.  COPD exacerbations: definitions and classifications.

Authors:  S Burge; J A Wedzicha
Journal:  Eur Respir J Suppl       Date:  2003-06
View more
  13 in total

1.  Different patterns of Toll-like receptor 2 polymorphisms in populations of various ethnic and geographic origins.

Authors:  M Ioana; B Ferwerda; T S Plantinga; M Stappers; M Oosting; M McCall; A Cimpoeru; F Burada; N Panduru; R Sauerwein; O Doumbo; J W M van der Meer; R van Crevel; L A B Joosten; M G Netea
Journal:  Infect Immun       Date:  2012-02-21       Impact factor: 3.441

2.  Cross-linking Proteomics Indicates Effects of Simvastatin on the TLR2 Interactome and Reveals ACTR1A as a Novel Regulator of the TLR2 Signal Cascade.

Authors:  Abu Hena Mostafa Kamal; Jim J Aloor; Michael B Fessler; Saiful M Chowdhury
Journal:  Mol Cell Proteomics       Date:  2019-06-20       Impact factor: 5.911

Review 3.  Association of TLR1, TLR2, TLR4, TLR6, and TIRAP polymorphisms with disease susceptibility.

Authors:  Mamoona Noreen; Muhammad Arshad
Journal:  Immunol Res       Date:  2015-06       Impact factor: 2.829

4.  Association between TLR2/TLR4 gene polymorphisms and COPD phenotype in a Greek cohort.

Authors:  A Apostolou; T Kerenidi; A Michopoulos; K I Gourgoulianis; M Noutsias; A E Germenis; M Speletas
Journal:  Herz       Date:  2016-12-01       Impact factor: 1.443

5.  Polymorphisms of Toll-like receptors (TLR2 and TLR4) are associated with the risk of infectious complications in acute myeloid leukemia.

Authors:  U Schnetzke; B Spies-Weisshart; O Yomade; M Fischer; T Rachow; K Schrenk; A Glaser; M von Lilienfeld-Toal; A Hochhaus; S Scholl
Journal:  Genes Immun       Date:  2014-11-27       Impact factor: 2.676

6.  Association of TLR4-T399I polymorphism with chronic obstructive pulmonary disease in smokers.

Authors:  Matthaios Speletas; Vassiliki Merentiti; Konstantinos Kostikas; Kyriaki Liadaki; Markos Minas; Konstantinos Gourgoulianis; Anastasios E Germenis
Journal:  Clin Dev Immunol       Date:  2010-02-15

Review 7.  Updates on the COPD gene list.

Authors:  Yohan Bossé
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2012-09-18

8.  ADAM33 gene polymorphisms in chronic obstructive pulmonary disease.

Authors:  S Pabst; C Pizarro Touron; A Gillissen; M Lennarz; I Tuleta; G Nickenig; D Skowasch; C Grohé
Journal:  Eur J Med Res       Date:  2009-12-07       Impact factor: 2.175

Review 9.  Pulmonary-intestinal cross-talk in mucosal inflammatory disease.

Authors:  S Keely; N J Talley; P M Hansbro
Journal:  Mucosal Immunol       Date:  2011-11-16       Impact factor: 7.313

10.  Toll-like receptor (TLR2 and TLR4) polymorphisms and chronic obstructive pulmonary disease.

Authors:  Simona E Budulac; H Marike Boezen; Pieter S Hiemstra; Therese S Lapperre; Judith M Vonk; Wim Timens; Dirkje S Postma
Journal:  PLoS One       Date:  2012-08-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.